Clinical Trial Update: Serum sST2/ miR-223 as a Dual Biomarker for Disease Activity & Clinical Efficacy of SLIT in HDM-Induced Allergic Rhinitis [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates serum biomarkers sST2 and miR-223 as dual indicators of disease activity and SLIT efficacy in allergic rhinitis; the study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Snippet

Sponsor: Zagazig University | Conditions: HDM-Induced Allergic Rhinitis | Phase 1 | Status: COMPLETED